|Chemical and physical data|
|Molar mass||142461.81 g·mol−1|
This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer. OncoMed was awarded a patent in 2016, which is set to expire in 2029. In April 2017, Bayer terminated its option to license vantictumab.
Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer and in 2020 for pancreatic cancer.
- "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. 28 Nov 2012. N12/155.(registration required)
- "OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance". 12 January 2015.
- "Annual Report on Form 10-K". OncoMed Pharmaceuticals, Inc. Archived from the original on 13 January 2017.
- "BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept". Reuters. 10 April 2017.
- "Finally, targeted therapies for triple-negative breast cancer". Medical Xpress. June 2016.
- Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, et al. (November 2020). "Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer". Breast Cancer Research and Treatment. 184 (1): 53–62. doi:10.1007/s10549-020-05817-w. PMC 7572714. PMID 32803633.
- Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, et al. (June 2020). "A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer". Investigational New Drugs. 38 (3): 821–830. doi:10.1007/s10637-019-00824-1. PMC 7211194. PMID 31338636.